Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.

MARKN.

Xbrane announces today that it has appointed Jane Benyamin as acting CFO as of January 9, 2025. As previously announced, the company's current CFO, Anette Lindqvist, is stepping down from the role of CFO with the intention of reducing her operational work to retire.

Jane has experience from several senior finance roles within Life Science from Bluefish Pharmaceuticals, Pensa Pharma and Medivir among others.

"I welcome Jane to Xbrane and I am convinced that her experience from the industry will be very valuable in the future," says Martin Åmark, CEO of Xbrane. "At the same time, I want to thank Anette Lindqvist for her valuable efforts as CFO and wish her all the best in the future"

Jane Benyamin will be acting CFO until further notice starting today, January 9, 2025. Anette Lindqvist will be available for a period to ensure a smooth transition.

Datum 2025-01-09, kl 14:00
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!